Gregory Enns, M.D.

Dr. Enns is a Professor of Pediatrics and Director of the Biochemical Genetics Program at Stanford University. After receiving his medical degree from the University of Glasgow, he trained in Pediatrics at Children's Hospital Los Angeles, and in Clinical Genetics and Clinical Biochemical Genetics at the University of California, San Francisco. 

He has extensive experience in the diagnosis and management of inborn errors of metabolism, including congenital disorders of glycosylation, mitochondrial disorders, and lysosomal storage disorders. Dr. Enns also performs translational research focusing on the development of a sensitive panel of redox biomarkers to study disorders of energy metabolism, and participates in clinical trials aimed at developing novel treatments for inborn errors of metabolism.

Matt Wilsey

Matt Wilsey is a Silicon Valley entrepreneur, angel investor, and advisor. In addition to consumer products and services, Matt invests in and advocates in biomedical research, drug development, and genetic sequencing technologies. Before moving to the investment side, he spent many years as a front-line operator. Most recently, Matt was Co-Founder and Chief Revenue Officer of Card Spring, a payment infrastructure company that was acquired by Twitter. Previously, Matt ran West coast sales and business development for Before Howcast, Matt worked for Kohlberg Kravis Roberts (KKR) on the Capital Markets team. Prior to that, Matt spent five years as a Co-Founder and Vice President of Business Development at

He started his career serving in various roles at the White House and the Department of Defense. Matt became a rare disease advocate after his daughter Grace was born with Ngly1 deficiency. The Grace Wilsey Foundation has founded 20 research teams accounting for over 50 scientists in 3 countries with the sole purpose of curing the disease. Matt holds a B.A. from Stanford University and a M.B.A. from Stanford’s Graduate School of Business.